Q-omics provides the consensus-scored AMZ2P2 profile across patient tissues and cancer cell-line models. AMZ2P2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, AMZ2P2 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, AMZ2P2 RNA expression shows 10,759 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, KIRC, and LSCC as cancer lineages where AMZ2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMZ2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMZ2P2 survival associations across molecular data types. AMZ2P2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMZ2P2 RNA expression–survival associations across cancer types. High AMZ2P2 expression shows unfavorable associations in UCS, KIRC, ACC, PAAD and LIHC, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for AMZ2P2 RNA expression.
This table summarizes AMZ2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AMZ2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMZ2P2 shows lower tumor expression in THCA, LUSC and KICH and higher tumor expression in KIRC, COAD and HNSC. The KIRC box plot shows higher AMZ2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.053, t-test p < 0.001).
This table shows molecular features associated with AMZ2P2 in patient tissues and cancer cell lines. In patient samples, AMZ2P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
